What Are Beta-Blockers?
Beta-blockers (beta-adrenergic receptor antagonists) are medications that block the effects of adrenaline (epinephrine) and noradrenaline on beta-adrenergic receptors in the heart, lungs, and blood vessels. They slow the heart rate, reduce the force of heart contractions, and lower blood pressure — making them useful for a wide range of cardiovascular and non-cardiovascular conditions.
Common beta-blockers include metoprolol (Lopressor, Toprol-XL), carvedilol (Coreg), atenolol (Tenormin), bisoprolol (Zebeta), propranolol (Inderal), labetalol (Trandate), and nebivolol (Bystolic).
How Beta-Blockers Work
The sympathetic nervous system uses adrenaline and noradrenaline to activate beta-adrenergic receptors. There are three main types:
- Beta-1 receptors — Primarily in the heart; activation increases heart rate and contractility
- Beta-2 receptors — Primarily in the lungs and blood vessels; activation causes bronchodilation and vasodilation
- Beta-3 receptors — In fat tissue; activation promotes fat breakdown
Beta-blockers competitively block these receptors. By blocking beta-1 receptors in the heart, they reduce heart rate (negative chronotropy) and contractility (negative inotropy), which reduces cardiac workload and oxygen demand. This is beneficial in heart failure, angina, and arrhythmias.
Types of Beta-Blockers
| Type | Selectivity | Examples | Key Feature |
|---|---|---|---|
| Cardioselective (beta-1 selective) | Primarily beta-1 | Metoprolol, atenolol, bisoprolol, nebivolol | Less bronchospasm; preferred in asthma/COPD (with caution) |
| Non-selective | Beta-1 and beta-2 | Propranolol, nadolol, timolol | Also blocks beta-2 (lungs, vessels); more side effects |
| Alpha + beta blocking | Beta-1, beta-2, and alpha-1 | Carvedilol, labetalol | Additional vasodilation via alpha-1 blockade; preferred in HFrEF |
What Are Beta-Blockers Used For?
| Indication | Evidence | Preferred Agent |
|---|---|---|
| Heart failure with reduced EF (HFrEF) | MERIT-HF, COPERNICUS, CIBIS-II: 34–35% mortality reduction | Carvedilol, metoprolol succinate, bisoprolol |
| Post-myocardial infarction | Reduces reinfarction and mortality | Metoprolol, carvedilol |
| Hypertension | Effective; no longer first-line per JNC 8 (unless compelling indication) | Metoprolol, atenolol, bisoprolol |
| Atrial fibrillation (rate control) | Effective for ventricular rate control | Metoprolol, atenolol, bisoprolol |
| Angina pectoris | Reduces angina frequency and exercise-induced ischemia | Metoprolol, atenolol, propranolol |
| Migraine prevention | Propranolol: FDA-approved for migraine prophylaxis | Propranolol, metoprolol |
| Essential tremor | Propranolol: FDA-approved | Propranolol |
| Performance anxiety | Off-label; reduces sympathetic symptoms | Propranolol (low dose) |
| Hyperthyroidism (symptomatic) | Controls tachycardia and tremor while awaiting definitive therapy | Propranolol, atenolol |
Side Effects of Beta-Blockers
Common Side Effects
- Fatigue and exercise intolerance — Reduced maximum heart rate limits exercise capacity; most common complaint
- Bradycardia — Heart rate below 60 bpm; usually asymptomatic but can cause dizziness
- Cold extremities — Reduced peripheral blood flow; hands and feet may feel cold
- Sexual dysfunction — Erectile dysfunction in men; more common with non-selective agents
- Weight gain — Modest weight gain (1–2 kg) common, especially with non-selective agents
- Depression — Reported but causality is debated; more common with lipophilic agents (propranolol)
Serious Side Effects
- Bronchospasm — Beta-2 blockade in the lungs can trigger bronchoconstriction; non-selective agents are more dangerous in asthma/COPD. Cardioselective agents (metoprolol, bisoprolol) can be used cautiously in mild-moderate COPD but are contraindicated in severe asthma.
- Masking of hypoglycemia — Beta-blockers blunt the tachycardia that warns diabetic patients of low blood sugar. Sweating is preserved. Cardioselective agents are preferred in diabetic patients.
- Rebound hypertension and angina — Abrupt discontinuation can cause rebound tachycardia, hypertension, and angina (even myocardial infarction). Always taper gradually.
Important Contraindications
- Cardiogenic shock or decompensated heart failure
- Severe bradycardia (<50 bpm) or high-degree AV block (without pacemaker)
- Severe reactive airway disease (asthma) — non-selective agents
- Cocaine toxicity — beta-blockers can worsen coronary spasm in cocaine-induced chest pain
Metoprolol vs Carvedilol: The Key Comparison
For heart failure with reduced ejection fraction (HFrEF), three beta-blockers have proven mortality benefit: carvedilol, metoprolol succinate (extended-release), and bisoprolol. Carvedilol is the only one with combined alpha+beta blockade, which provides additional vasodilation. The COMET trial (2003) found carvedilol reduced all-cause mortality by 17% more than metoprolol tartrate (immediate-release) in HFrEF — though this comparison used the immediate-release form of metoprolol, which is less effective than the extended-release form. For most HFrEF patients, any of the three proven agents is appropriate.
Can You Stop Beta-Blockers Suddenly?
No. Abrupt discontinuation of beta-blockers can cause rebound tachycardia, severe hypertension, and worsening angina — and has been associated with myocardial infarction in patients with coronary artery disease. Beta-blockers should always be tapered gradually over 1–2 weeks when discontinuation is necessary. See our article on stopping beta-blockers safely for a detailed tapering guide.
Cost and Generic Availability
Most beta-blockers are available as generics at very low cost. Metoprolol succinate (extended-release) typically costs $10–$25/month. Carvedilol is $10–$20/month. Atenolol is $4–$10/month. See our metoprolol cost guide for current pricing.
References
- MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007.
- Packer M, et al. Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS). N Engl J Med. 2001;344(22):1651-1658.
- Poole-Wilson PA, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET). Lancet. 2003;362(9377):7-13.
Save up to 80% on this medication
Use a free RxGo discount card at 67,000+ pharmacies — no sign-up, no insurance needed.
About the Author
James Okafor, RPh, MBA
Registered Pharmacist & Health Economics Writer
James Okafor is a registered pharmacist with over 12 years of experience in retail and clinical pharmacy settings. He holds an MBA with a focus on healthcare management and specializes in translating complex drug pricing, formulary, and insurance coverage topics into clear, actionable guidance for patients. Before joining RxGuide, James worked as a clinical pharmacist at a regional hospital system and as a pharmacy benefits consultant for a national PBM. His writing focuses on cost transparency, generic alternatives, and helping patients navigate the U.S. prescription drug system.
View full profile on our Editorial Team page →Get the RxGo app — free prescription discounts on the go
Works at 67,000+ pharmacies · No membership needed